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Abstract
Background: Dry eye is a multifactor disease of the tear film and ocular surface that substantially affects quality of
life.
Case presentation: Dobesilate administered as eye drops was well tolerated and effective in treating both the
objective signs and subjective symptoms of dry eye disease in this 2-week study.
Conclusion: To the best of our knowledge, this is the first clinical report of using dobesilate in eye drops.
Dobesilate may provide a novel approach to treating drying diseases of the eye.
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Background
Dry eye disease (DED) is a progressive and multifactorial
disease affecting the tear film and ocular surface that
causes discomfort, visual disturbances and tear film in-
stability with potential damage to the ocular surface [1].
DED is one of the most common ophthalmic problems,
and it is estimated that up to one-third of the global
population may be affected. Although the pathogenesis
of DED is not fully understood, it is recognized that in-
flammation has a prominent role in the development and
amplification of the signs and symptoms of DED [2–5].
Accordingly, successful application of anti-inflammatory
medications in the treatment of DED provides hope for
the millions of individuals who suffer from this deleterious
condition. Herein, we report the safety and effectiveness
of topical administration of the anti-inflammatory drug
dobesilate [6–9] in patients with severe DED.
Patients and treatment
Eight patients (seven women and one man) with severe
DED in both eyes participated in this study. The study
was approved by our institutional ethical committee, and
patients signed an informed consent form that included
a comprehensive description of the proposed procedure
with dobesilate. Patients were asked before and during
treatment to describe the DED symptoms they experi-
enced. DED symptoms (foreign body sensation, dryness,
photophobia, eye pain, and blurred vision) were scored
from 0 to 4, with a score of 0 indicating no symptoms
and a score of 4 indicating very severe symptoms. DED
signs were assessed by Schirmer’s tear test (STT) and by
fluorescence corneal staining (FCS). STT performed
without anesthesia measures tear volume. For FCS, 5 μl
of 0.5 % fluorescein solution was instilled in the con-
junctival sac. Fluorescein diffuses rapidly into the corneal
stroma when there is a loss of epithelial integrity. Corneal
staining was examined under standard illumination using
a slit-lamp microscope with a cobalt filter. All patients ini-
tially had STT scores <5 mm/5 min and corneal epithelio-
pathy in both eyes. DED symptom scores and signs were
compared at baseline, the second week of treatment, and
4 weeks after treatment discontinuation.
Furthermore, patient satisfaction scores were assessed
during treatment using four questions adapted from the
Study Group on Impact of Dry Eye on Everyday Life
(IDEEL) questionnaire [10], with minor modifications.
The four questions included the following: 1) my eyes
feel dry in the morning, 2) my eyes feel dry at the end of
the day, 3) my eyes feel refreshed when I use dobesilate,
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and 4) I frequently forget my symptoms when I use
dobesilate.
Patients consented to treatment with dobesilate eye
drops, which were prepared in the pharmacy service of
our institution. Patients self-administered dobesilate eye
drops (1 drop/eye/twice a day) for 2 weeks. Dobesilate
was used as a 12.5 % solution of diethylammonium 2-
5-dihydroxybenzene sulfonate (etamsylate, Dicynone®,
Sanofi-Aventis, Paris, France). Quantitative compari-
sons between baseline and post-treatment symptom
scores were performed for 16 eyes (8 patients) using
paired t-tests. A p value less than 0.05 was considered
statistically significant.
Symptoms of DED were significantly improved in
all patients after treatment (Fig. 1). In addition, STT
and corneal epitheliopathy assessed by FCS studies
improved significantly. Furthermore, patients exhibited
good compliance and did not report any adverse ef-
fects related to dobesilate treatment. As an example
of the effectiveness of dobesilate eye drops, we present a
patient with severe DED who participated in the present
study.
Case presentation
This is a representative case selected from among the
eight patients with DED who were treated with dobesi-
late eye drops. A 68-year-old Caucasian woman with a
five-year clinical history of DED in both eyes presented
with obvious ocular symptoms. The patient had been
previously treated with artificial tears, but without suc-
cess. STT scores were <5 mm/5 min in both eyes. Punc-
tuate epithelial erosions on the inferior corneal surface
were present in both eyes (Fig. 2). These punctuate
corneal epitheliopathies were most noticeable in the
right eye (Fig. 2). Furthermore, the right eye showed
a conspicuous corneal erosion (Fig. 2). These findings in-
dicated a severe DED.
After 2 weeks of dobesilate treatment, STT scores
improved in both eyes to 12 mm/5 min in the right eye
and 15 mm/5 min in the left eye. Corneal epitheliopathy
improved as well, and corneal healing was practically
achieved at the same time (Fig. 2). In addition, the pa-
tient’s subjective symptoms improved significantly after
2 weeks of treatment. At 4 weeks after treatment discon-
tinuation, the STT score was 15 mm/5 min in the right
eye and 20 mm/5 min in the left eye, and the corneal ul-
ceration of the right eye was healed (Fig. 3). The patient
exhibited good compliance to dobesilate treatment; the
data showed optimal tolerability, a lack of adverse effects
upon instillation and high patient satisfaction. In par-
ticular, the patient did not report any adverse events of
blurring, itching or scratching upon instillation. Instead,
the patient reported a statistically significant reduction
in all subjective symptoms. Objective and subjective data
were recorded at 4 weeks after treatment discontinu-
ation, and the patient reporting using artificial tears only
sporadically.
Discussion and conclusion
Dry eye is defined by the International Dry Eye Workshop
as a multifactor disease of the tear film and ocular surface
[1] that substantially affects quality of life because of
symptoms that include pain and irritation. DED has a
negative effect on ocular health and the patient’s general
Fig. 1 Improvement of dry eye symptoms after dobesilate eye drop instillation for two weeks. Data from 16 eyes (8 patients) are expressed as the
mean ± SEM *** indicate p < 0.001 vs. baseline by paired t-test
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health and well-being, as DED often disrupts daily activ-
ities [11, 12]. This condition is more prevalent in women
and increases with age. The prevalence of DED in the
population has been reported to be as high as 34 %
[13, 14], constituting a public health problem and an
economic burden [15]. Risk factors for the development of
DED include advanced age, female sex, hormonal imbal-
ance, autoimmune disease, vitamin deficiency, abnormal
corneal innervation, environmental stress, contact lens
use, medication, computer use, and ophthalmic sur-
gery [8].
The ocular surface (cornea, conjunctiva and accessory
lachrymal glands), meibomian glands, main lachrymal
gland and interconnecting neural reflex loops constitute
a functional unit [16]. In DED, inflammation affects all
of the components in the functional unit, which suggests
that immunological circuits are an integrate part of the
system [2, 17, 18]. Its central core is characterized by
cyclic events that interconnect tear film instability, tear
hyperosmolarity, local inflammatory responses and
metaplastic changes in the ocular surface epithelia. The
purpose of any therapeutic approach is to interrupt this
type of cycle at any point to slow or prevent the disease
progression [8].
The recommended treatments for mild DED are life-
style changes and use of artificial tears [17]; however,
frequent instillation is often required. Furthermore, pa-
tients with moderate to severe disease may require anti-
inflammatory medications or surgery [17]. Cyclosporine
ophthalmic emulsion has been approved by the United
States Food and Drug Administration for treating mod-
erate to severe DED. Clinical data indicate that long-
term treatment with cyclosporine A 0.05 % ophthalmic
emulsion can yield positive results with regard to object-
ive and subjective findings, including corneal surface
staining, STT scores, blurred vision, and frequency of
artificial tear application [19]. However, some patients
experience bothersome adverse effects (e.g., pain, burn-
ing or irritation) that impact medication tolerability.
Topical corticosteroid treatment has demonstrated effi-
cacy in clinical trials at diminishing symptom severity
and minimizing ocular surface staining in patients with
DED [20, 21]. Systemic corticosteroid administration
may also be effective in the management of DED [22].
Unfortunately, long-term topical or systemic corticoster-
oid use is associated with deleterious adverse effects,
Fig. 2 Slit-lamp fluorescein corneal staining pictures showed that inferior corneal punctuate epitheliopathy disappeared within 2 weeks of the
instillation of dobesilate eye drops. The corneal erosion (*) improved 2 weeks after administration of the drug
Fig. 3 Slit-lamp fluorescein corneal staining image of the right eye
showing complete resolution of corneal ulceration 4 weeks after
treatment discontinuation
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such as ocular hypertension, risk of cataract formation
and opportunistic infections. Orally administered anti-
inflammatory tetracycline derivatives have been used to
treat DED secondary to ocular rosacea and blepharitis [23].
However, despite extensive evidence from experimental tri-
als indicating their potential benefits in treating DED, there
is limited clinical evidence of their efficacy.
Because existing DED treatments have serious con-
cerns, the search for a safe and efficient therapy for DED
is urgently needed. Inflammation of the ocular surface in
DED is sustained by ongoing activation and infiltration
of pathogenic immune cells, primarily of the CD4+ T
cell compartment [24]. These biological processes were
favored and maintained by lymphangiogenesis [25]. Inter-
estingly, targeting prolymphangiogenic growth factors,
such as vascular endothelial growth factor (VEGF), or
their receptors improved murine DED, which is reflected
by decreased inflammation [26]. It was reported that
fibroblast growth factor (FGF) simultaneously provokes
hemangiogenesis and lymphangiogenesis on the cornea
through differential expression of VEGF [27]. Thus, inhib-
ition of FGF-driving inflammatory lymphangiogenesis is a
potential therapeutic target for DED.
Dobesilate, a drug with a long history of clinical safety
[28], has been used for many years as a vasculotropic
drug. Recently, it was reported that dobesilate is a
powerful inhibitor of FGF [29], which is a potent pro-
inflammatory protein [30, 31]. FGF is a strict mediator
of VEGF activities [29, 32, 33], and some of these activ-
ities were also abolished by dobesilate [34]. Dobesilate
shows a marked anti-inflammatory activity in several
inflammation-dependent diseases and inflammation models
[6–9]. Thus, it seems obvious that these activities may, at
least in part, contribute to an improvement in the signs and
symptoms of DED, which was observed with dobesilate
treatment in the present report.
The results of our study are very encouraging because
of the magnitude and consistency of the patients’ re-
sponses to the treatment and the rarity of spontaneous
improvements in patients with DED. Although further
large-scale therapeutic trials are necessary to definitively
establish the efficacy of this treatment, the results pre-
sented in this report seem to provide a basis for undertak-
ing these trials.
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